Search

Your search keyword '"Behrens, F"' showing total 855 results
Start Over Author "Behrens, F"
855 results on '"Behrens, F"'

6. LBA0005 EFFICACY AND SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 16 RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2b/3 STUDY

Author

Mease, P. J., primary, Behrens, F., additional, Kivitz, A., additional, Drescher, E., additional, Klimiuk, P. A., additional, Sofen, H., additional, Soloman, N., additional, Stevens, A. M., additional, Tomas, M. E., additional, Wiens, B., additional, Mpofu, S., additional, and Taylor, P. C., additional

Published
2024
Full Text
View/download PDF

14. OC 02.1 Dose-Dependent Elimination of HPA-1a Platelets by Subcutaneous RLYB212, a Monoclonal Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Author

Geisen, C., primary, Fleck, E., additional, Gastón Schäfer, S., additional, Walter, C., additional, Braeuninger, S., additional, Søndergaard Jensen, J., additional, Armstrong, R., additional, Sheridan, D., additional, Patki, K., additional, Kjaer, M., additional, Behrens, F., additional, Seifried, E., additional, Kjeldsen-Kragh, J., additional, and Köhm, M., additional

Published
2023
Full Text
View/download PDF

15. Versorgungssituation von Patienten mit ankylosierender Spondylitis und Psoriasisarthritis in Deutschland: Versorgungssituation von Patienten mit Spondyloarthritis (SpA): Ankylosierende Spondylitis (AS) und Psoriasisarthritis (PsA) aus der Sicht von niedergelassenen und in Kliniken tätigen Rheumatologen in Deutschland – Ergebnisse des Forschungsprojekts „SpA Loop – Life of Outpatients“

Author

Braun, J., Schwarting, A., Hammel, L., Legeler, C., Wimmer, P., Färber, L., and Behrens, F.

Published
2019
Full Text
View/download PDF

16. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Author

Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC, Clinical Immunology and Rheumatology, and AII - Inflammatory diseases

Subjects
General Medicine
Abstract

Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α (TNFα) inhibitors. Methods: BE COMPLETE was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial conducted across 92 sites (including hospitals, clinics, and research centres) in 11 countries (Australia, Canada, Czech Republic, Germany, Hungary, Italy, Japan, Poland, Russia, the UK, and the USA). Eligible patients were aged 18 years or older with adult-onset psoriatic arthritis (meeting the Classification Criteria for Psoriatic Arthritis for at least 6 months before screening) with a history of inadequate response or intolerance to treatment with one or two TNFα inhibitors for either psoriatic arthritis or psoriasis. We stratified patients with active psoriatic arthritis by region and previous TNFα inhibitor use. Patients were randomly assigned (2:1) to receive subcutaneous bimekizumab 160 mg every 4 weeks or placebo by an interactive-voice and web-response system on the basis of a predetermined randomisation schedule. The primary endpoint was the proportion of patients with 50% or greater improvement in American College of Rheumatology criteria (ACR50) at week 16 (non-responder imputation). Efficacy analyses were done in the randomised population. The safety analysis set comprised patients who received one or more doses of study treatment. This trial was registered at ClinicalTrials.gov, NCT03896581, and is completed. Findings: Between March 28, 2019, and Feb 14, 2022, 556 patients were screened and 400 patients were randomly assigned to bimekizumab 160 mg every 4 weeks (n=267) or placebo (n=133). The primary and all hierarchical secondary endpoints were met at week 16. 116 (43%) of 267 patients receiving bimekizumab reached ACR50, compared with nine (7%) of 133 patients receiving placebo (adjusted odds ratio [OR] 11·1 [95% CI 5·4–23·0], p Interpretation: Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes at week 16 compared with placebo in patients with psoriatic arthritis and inadequate response or intolerance to TNFα inhibitors. The safety profile of bimekizumab was consistent with previous phase 3 studies in patients with plaque psoriasis, and studies of IL-17A inhibitors.

Published
2023

19. Sicherheit und Wirksamkeitshinweise zum Off-label-Einsatz von Biologikatherapien nach Versagen konventioneller Therapien bei Patienten mit entzündlich rheumatischen Erkrankungen: Ergebnisse eines nationalen Registers (GRAID2)

Author

Proft, F., Schulze-Koops, H., Grunke, M., Schrezenmeier, E., Halleck, F., Henes, J., Unger, L., Schmidt, E., Fiehn, C., Jacobi, A., Iking-Konert, C., Kneitz, C., Schmidt, R. E., Bannert, B., Voll, R. E., Fischer-Betz, R., Kötter, I., Tony, H. P., Holle, J., Aringer, M., Erler, A., Behrens, F., Burmester, G. R., and Dörner, T.

Published
2018
Full Text
View/download PDF

21. POS0181 THE IMPACT OF AUTOANTIBODIES (RF AND ACPA) ON THE EFFICACY OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Author

Takase-Minegishi, K., primary, Böhringer, S., additional, Nam, J., additional, Kaneko, Y., additional, Behrens, F., additional, Saevarsdottir, S., additional, Detert, J., additional, Leirisalo-Repo, M., additional, Van der Heijde, D., additional, Landewé, R. B. M., additional, Ramiro, S., additional, and Van der Woude, D., additional

Published
2023
Full Text
View/download PDF

22. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR

Author

Coates, L., primary, Landewé, R. B. M., additional, Mcinnes, I., additional, Mease, P. J., additional, Ritchlin, C. T., additional, Tanaka, Y., additional, Asahina, A., additional, Behrens, F., additional, Gladman, D. D., additional, Gossec, L., additional, Gottlieb, A. B., additional, Warren, R. B., additional, Ink, B., additional, Bajracharya, R., additional, Coarse, J., additional, and Merola, J. F., additional

Published
2023
Full Text
View/download PDF

23. POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL

Author

Mcinnes, I., primary, Mease, P. J., additional, Tanaka, Y., additional, Behrens, F., additional, Gossec, L., additional, Husni, M. E., additional, Kristensen, L. E., additional, Warren, R. B., additional, Ink, B., additional, Bajracharya, R., additional, Coarse, J., additional, Eells, J., additional, and Gottlieb, A. B., additional

Published
2023
Full Text
View/download PDF

24. POS1547 EFFICACY OF UST IN ACTIVE PSA MONITORED BY MUSCULOSKELETAL ULTRASOUND IS INDEPENDENT FROM CONCOMITANT MTX USE: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL

Author

Köhm, M., primary, Foldenauer, A. C., additional, Rossmanith, T., additional, Wassenberg, S., additional, Finzel, S., additional, Kleyer, A., additional, Bergner, R., additional, Alten, R., additional, Kellner, H., additional, Walter, J., additional, Kästner, P., additional, and Behrens, F., additional

Published
2023
Full Text
View/download PDF

25. POS0229 COMBINING MTX DOES NOT RESULT IN AN ADDITIONAL EFFICACY OF UST TREATMENT IN POLYARTHRITIC PSA: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL

Author

Köhm, M., primary, Foldenauer, A. C., additional, Rossmanith, T., additional, Kellner, H., additional, Kiltz, U., additional, Kleyer, A., additional, Burmester, G. R., additional, Brandt-Juergens, J., additional, Kofler, D. M., additional, Burkhardt, H., additional, and Behrens, F., additional

Published
2023
Full Text
View/download PDF

31. Le bimékizumab réduit fatigue et douleur chez les patients atteints de rhumatisme psoriasique actif, naïfs de biologiques ou avec réponse inadéquate (RI) aux anti-TNF : résultats à 16 semaines de 2 études de phase III randomisées, contrôlées par placebo

Author

Gossec, L., primary, Husni, M.E., additional, Mease, P.J., additional, Merola, J.F., additional, Behrens, F., additional, Favalli, E.G., additional, McGonagle, D., additional, Tillett, W., additional, Tsuji, S., additional, Ink, B., additional, Assudani, D., additional, Bajracharya, R., additional, Coarse, J., additional, and Lambert, J., additional

Published
2022
Full Text
View/download PDF

32. Le bimékizumab chez des patients atteints de rhumatisme psoriasique et présentant une réponse inadéquate aux anti-TNF : évaluation de l’efficacité et de la tolérance à 16 semaines dans une étude de phase III

Author

Gossec, L., primary, Merola, J.F., additional, McInnes, I.B., additional, Ritchlin, C.T., additional, Mease, P.J., additional, Landewé, R.B., additional, Asahina, A., additional, Tanaka, Y., additional, Warren, R.B., additional, Gladman, D.D., additional, Behrens, F., additional, Ink, B., additional, Assudani, D., additional, Bajracharya, R., additional, Coarse, J., additional, and Coates, L.C., additional

Published
2022
Full Text
View/download PDF

35. Merkmale von Patient*innen mit Psoriasis-Arthritis in dermatologischer und rheumatologischer Versorgung: Eine Analyse zweier Krankheitsregister

Author

Kühl, L, Lindner, L, Augustin, M, Weiss, A, Rustenbach, SJ, Mrowietz, U, Behrens, F, Strangfeld, A, and Regierer, A

Subjects
ddc: 610, Medicine and health
Abstract

Hintergrund und Stand (inter)nationaler Forschung: Die Psoriasis-Arthritis (PsA) ist eine chronisch entzündliche Erkrankung, die den Bewegungsapparat, die Haut und die Nägel betrifft. Die Diagnose und Versorgung der PsA-Patient*innen erfolgt in Deutschland in der Regel durch Dermatolog*innen [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

36. Arthropods as vectors of esca-related pathogens: Transmission efficiency of ants and earwigs and the potential of earwig feces as inoculum source in vineyards

Author

Kalvelage, E. M., Behrens, F. H., Rauch, C., Voegele, R. T., and Fischer, M.

Subjects
fungi
Abstract

The spread of Grapevine trunk diseases (GTDs) such as esca concerns wine growers worldwide. Besides rain-splash and air currents, arthropods may play an additional role in the dissemination of esca-related pathogens such as Phaeomoniella chlamydospora (Pch) and Phaeoacremonium minimum (Pmm). The present study confirms that black garden ants (Lasius niger L., Formicidae: Formicinae) and European earwigs (Forficula auricularia L., Dermaptera: Forficulidae) can, under artificial conditions, efficiently transmit spores of Pch and Pmm to healthy grapevine cuttings, causing new infections. The potential of earwig feces as inoculum source in vineyards is additionally discussed. Spores of Pch and Pmm retained germination ability after earwig gut passage, and infectious feces successfully infected wounded grapevine cuttings under artificial conditions. However, molecular detection frequencies of esca-related pathogens in earwig feces collected from the field were very low. With this, the risk of earwig feces as inoculum source for esca-related pathogens is probably only marginal. However, arthropods carrying esca-related spores on their exoskeletons, such as ants and earwigs, might contribute to the overall spread of esca in vineyards. The invasion of GTDs during the phase of pruning wound susceptibility, either by arthropod vectors or by airborne spores, can efficiently be prevented by adequate pruning wound protection., VITIS - Journal of Grapevine Research, Vol. 61 No. 2 (2022): Vitis

Published
2022
Full Text
View/download PDF

38. Brauchen wir noch klinische Studien in der Rheumatologie?

Author

Henkemeier, U., Alten, R., Bannert, B., Baraliakos, X., Behrens, F., Heldmann, F., Kiltz, U., Köhm, M., König, R., Leipe, J., Müller-Ladner, U., Rech, J., Riechers, E., Rubbert-Roth, A., Schmidt, R.E., Schulze-Koops, H., Specker, C., Tausche, A.-K., Wassenberg, S., Witt, M., Witte, T., Zernicke, J., and Burkhardt, H.

Published
2016
Full Text
View/download PDF

41. Entwicklung eines unterstützenden Systems zur Befundanalyse und Versorgungsverbesserung bei Patienten mit Psoriasis Arthritis und axialer Spondylarthritis mithilfe von Künstliche Intelligenz- und Natural Language Processing-Methoden

Author

Kratz, H, Ginzel, S, Ohrndorf, S, Baraliakos, X, Tsiami, S, Haedecke, E, Doll, N, Holz-Müller, J, Rüping, S, Behrens, F, Köhm, M, Kratz, H, Ginzel, S, Ohrndorf, S, Baraliakos, X, Tsiami, S, Haedecke, E, Doll, N, Holz-Müller, J, Rüping, S, Behrens, F, and Köhm, M

Published
2022

43. Die 'ARIAA-Studie' - Abatacept verzögert den Übergang in eine RA bei at-risk-Patienten - klinische Ergebnisse zu Monat 18 der internationalen, randomisiert, placebo kontrollierten Studie

Author

Rech, J, Kleyer, A, Ostergaard, M, Feuchtenberger, M, Hagen, M, Valor Mendez, L, Koray, T, Kroenke, G, Schönau, V, Kleinert, S, Baraliakos, X, Braun, J, Fleck, M, Rubbert-Roth, A, Behrens, F, Zaenker, M, Kofler, DM, Simon, D, Glaser, C, Hueber, A, Voll, R, Feist, E, Burmester, GR, Karberg, K, Strunk, J, Cañete, JdD, Senolt, L, Naredo, E, Schett, G, Rech, J, Kleyer, A, Ostergaard, M, Feuchtenberger, M, Hagen, M, Valor Mendez, L, Koray, T, Kroenke, G, Schönau, V, Kleinert, S, Baraliakos, X, Braun, J, Fleck, M, Rubbert-Roth, A, Behrens, F, Zaenker, M, Kofler, DM, Simon, D, Glaser, C, Hueber, A, Voll, R, Feist, E, Burmester, GR, Karberg, K, Strunk, J, Cañete, JdD, Senolt, L, Naredo, E, and Schett, G

Published
2022

44. Add-on or withdrawal of methotrexate do not impact efficacy of IL12/23 inhibition in active PsA: Data from the multicenter investigator-initiated randomized placebo-controlled MUST trial

Author

Köhm, M, Rossmanith, T, Foldenauer, AC, Kellner, H, Kiltz, U, Rech, J, Burmester, GR, Kofler, D, Brandt-Jürgens, J, Braun, J, Finzel, S, Bergner, R, Sieburg, M, Kästner, P, Jonetzko, C, Burkhardt, H, Behrens, F, Köhm, M, Rossmanith, T, Foldenauer, AC, Kellner, H, Kiltz, U, Rech, J, Burmester, GR, Kofler, D, Brandt-Jürgens, J, Braun, J, Finzel, S, Bergner, R, Sieburg, M, Kästner, P, Jonetzko, C, Burkhardt, H, and Behrens, F

Published
2022

46. Charakterisierung von Patient*innen mit Psoriasis-Arthritis in dermatologischer und rheumatologischer Versorgung: Eine Analyse zweier Krankheitsregister

Author

Lindner, L, Augustin, M, Kühl, L, Weiß, A, Rustenbach, S, Baraliakos, X, Feuchtenberger, M, Mrowietz, U, Thaci, D, Staubach, P, Behrens, F, Strangfeld, A, Regierer, A, Lindner, L, Augustin, M, Kühl, L, Weiß, A, Rustenbach, S, Baraliakos, X, Feuchtenberger, M, Mrowietz, U, Thaci, D, Staubach, P, Behrens, F, Strangfeld, A, and Regierer, A

Published
2022

47. ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS

Author

Rech, J., Kleyer, A., Ostergaard, M., Hagen, M., Valor, L., Tascilar, K., Kronke, G., Schonau, V., Kleinert, S., Baraliakos, X., Braun, J., Fleck, M., Rubbert-Roth, A., Behrens, F., Feuchtenberger, M., Zaenker, M., Kofler, D. M., Voll, R., Glaser, C., Hueber, A., Feist, E., Burmester, G. R., Karberg, K., Strunk, J., Canete, J. D. D., Senolt, L., Naredo, E., Schett, G., Rech, J., Kleyer, A., Ostergaard, M., Hagen, M., Valor, L., Tascilar, K., Kronke, G., Schonau, V., Kleinert, S., Baraliakos, X., Braun, J., Fleck, M., Rubbert-Roth, A., Behrens, F., Feuchtenberger, M., Zaenker, M., Kofler, D. M., Voll, R., Glaser, C., Hueber, A., Feist, E., Burmester, G. R., Karberg, K., Strunk, J., Canete, J. D. D., Senolt, L., Naredo, E., and Schett, G.

Published
2022

48. EFFICACY OF UST IN ACTIVE PSA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL

Author

Koehm, M., Rossmanith, T., Foldenauer, A. C., Kellner, H., Kiltz, U., Rech, J., Burmester, G. R., Kofler, D. M., Brandt-Juergens, J., Jonetzko, C., Burkhardt, H., Behrens, F., Koehm, M., Rossmanith, T., Foldenauer, A. C., Kellner, H., Kiltz, U., Rech, J., Burmester, G. R., Kofler, D. M., Brandt-Juergens, J., Jonetzko, C., Burkhardt, H., and Behrens, F.

Published
2022

50. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Author

Clowse, Megan E. B., Wallace, Daniel J., Furie, Richard A., Petri, Michelle A., Pike, Marilyn C., Leszczyński, Piotr, Neuwelt, C. Michael, Hobbs, Kathryn, Keiserman, Mauro, Duca, Liliana, Kalunian, Kenneth C., Galateanu, Catrinel, Bongardt, Sabine, Stach, Christian, Beaudot, Carolyn, Kilgallen, Brian, Gordon, Caroline, Batalov, A., Bojinca, M., Djerassi, R., Duca, L., Horak, P., Kolarov, Z., Milasiene, R., Monova, D., Otsa, K., Pileckyte, M., Popova, T., Radulescu, F., Rashkov, R., Rednic, S., Repin, M., Stoilov, R., Tegzova, D., Vezikova, N., Vitek, P., Zainea, C., East, Far, Baek, H., Chen, Y., Chiu, Y., Cho, C., Chou, C., Choe, J., Huang, C., Kang, Y., Kang, S., Lai, N., Lee, S., Park, W., Shim, S., Suh, C., Yoo, W., Armengol, H. Avila, Zapata, F. Avila, Santiago, M. Barreto, Cavalcanti, F., Chahade, W., Costallat, L., Keiserman, M., Alcala, J. Orozco, Remus, C. Ramos, Roimicher, L., AbuShakra, M., Agarwal, V., AgmonLevin, N., Kadel, J., Levy, Y., Mevorach, D., Paran, D., Reitblat, T., Rosner, I., Shobha, V., Sthoeger, Z., Zisman, D., Ayesu, K., Berney, S., Box, J., Busch, H., Buyon, J., Carter, J., Chi, J., Clowse, M., Collins, R., Dao, K., Diab, I., Dikranian, A., ElShahawy, M., Gaylis, N., Grossman, J., Halpert, E., Huff, J., Jarjour, W., Kao, A., Katz, R., Kennedy, A., Khan, M., Kivitz, A., Kohen, M., LawrenceFord, T., Lawson, J., Levesque, M., Lowenstein, M., Majjhoo, A., Mcarthur, R., McLain, D., Merrill, J., Murillo, A., Neucks, S., Niemer, G., Noaiseh, G., Parker, C., Pantojas, C., Pattanaik, D., Petri, M., Pickrell, P., Reveille, J., RomanMiranda, A., Rothfield, N., Sankoorikal, A., Sayers, M., Singhal, A., Snyder, A., Striebich, C., Vo, Q., von Feldt, J., Wallace, D., Wasko, M., Young, C., Adelstein, S., Hall, S., Littlejohn, G., Nicholls, D., Suranyi, M., Amoura, Z., Bannert, B., Behrens, F., Perez, L.Carreno, Chakravarty, K., Gonzales, F. Diaz, Davies, K., Doria, A., Emery, P., FernándezNebro, A., Govoni, M., Hachulla, E., Hellmich, B., Houssiau, F., Malaise, M., Margaux, J., Maugars, Y., MuñozFernández, S., Navarro, F., OrdiRos, J., Pellerito, R., PenaSagredo, J., Roussou, E., Schmidt, R. E., UcarAngulo, E., Viallard, JF., Westhovens, R., Worm, M., Yee, C. S., Nayiager, S., Reuter, H., Spargo, C., Bazela, B., Brzosko, M., Chudzik, D., Gasztonyi, B., Geher, P., Ionescu, R., Jeka, S., Kemeny, L., Kiss, E., Kotyla, P., Kovacs, L., Kovalenko, V., Kucharz, E., Kwiatkowska, B., Leszczynski, P., Levchenko, E., Lysenko, G., Majdan, M., Mihailov, C., Nalotov, S., Nedelciu, M., Pavel, M., Raskina, T., Rebrov, B., Rezus, E., Semen, T., Smakotina, S., Stanislavchuk, M., Stanislav, M., Szombati, I., Szucs, G., Udrea, G., Zajdel, J., ZonGiebel, A., Bonfiglioli, R., Bustamante, R., Klumb, E., Ramirez, G. Medrano, Neiva, C., Olguin, M., Gonzaga, J.Reyes, Scotton, A., Ayala, S. Sicsik, Ximenes, A., Sharma, R., Srikantiah, C., Aelion, J., Aranow, C., Baker, M., Chadha, A., Chao, J., Chatham, W., Chow, A., Clay, C., CohenGadol, S., Conaway, D., Denburg, J., Escalante, A., Espinoza, L., Fiechtner, J., Fortin, I., Fraser, A., Furie, R., Gladman, D., Goddard, D., Goldberg, M., GonzalezRivera, R., Gorman, J., Griffin, R., Haaland, D., Halter, D., Hemaiden, A., Hobbs, K., Joshi, V., Lim, S., Kalunian, K., Karpouzas, G., Khraishi, M., Lafyatis, R., Lee, S., Lidman, R., Lue, C., Mohan, M., Mease, P., Mehta, C., Mizutani, W., Nami, A., Nascimento, J., Neuwelt, C., Pappas, J., Pope, J., Porges, A., Roane, G., Rosenberg, D., Ross, S., Saadeh, C., Scoville, C., Sherrer, Y., Solomon, M., Surbeck, W., Valenzuela, G., Waller, P., Alten, R., Baerwald, C., Bienvenu, B., Bombardieri, S., Braun, J., Dival, L., Espinosa, G., Fernandez, I. Figueroa, GomezReino, J., Gordon, C., Hiepe, F., Hopkinson, N., Isenberg, D., Jacobi, A., Jorgensen, C., Guern, V. Le, Paul, C., PegoReigosa, J. M., Heredia, J. Rodriguez, RubbertRoth, A., Sabbadini, M., Schroeder, J., Schwarting, A., Spieler, W., Valesini, G., Wollenhaupt, J., Mendoza, A. Zea, and Zouboulis, C.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results